The SLAS 2022 Call for Abstracts submission period is also a Call for Abstracts contest. You can now submit a podium or poster abstract and receive a Hype Ticket. This allows one entry into the monthly drawing for a year-long APPLIED subscription as well… Read More
Natural killer (NK) cell therapies have the potential to be an effective, off-the-shelf treatment for a range of cancers. Analysis of NK cell therapies, currently in development, reveals that 57% of these are allogeneic therapies, and although development in haematological indications is more advanced, there are a high number of therapies… Read More
In this video, Dr Gary Allenby, CEO Aurelia Bioscience, describes a scientific poster on ‘Protein-protein Interactions Using NanoBRET Technology’. Historically, only solution-based assays were used to screen compounds in PPI, but a more physiological approach is to examine the interaction in living cells. However, there are very few… Read More
A new study is trialling whether giving aspirin alongside immunotherapy drug avelumab could improve its effectiveness for people affected by breast cancer. The clinical trial is being funded by the Breast Cancer Now Catalyst Programme, which aims to accelerate progress in breast cancer research through innovation and collaboration. As… Read More
Following a thorough review of evidence carried out by the Medicines and Healthcare products Regulatory Agency (MHRA) and recommendation by the Commission on Human Medicines (CHM), the UK government’s independent expert scientific advisory body, the MHRA has approved Ronapreve as the first monoclonal antibody combination product indicated for use in the… Read More
Avacta has appointed Dr Mark Goldberg as Non-executive Director to the Board with immediate effect. Dr Alastair Smith, Chief Executive Officer of Avacta, said Goldberg’s experience as a biotech executive and oncologist will greatly benefit the strategy and vision for the therapeutic business. Dr Goldberg is a medical oncologist and haematologist on the faculty… Read More
News round-up by DDW’s Megan Thomas for 16-20 August DDW’s Megan Thomas selects five news stories which spotlight the deals, collaborations and funding keeping the industry moving forward, enabling academics and drug developers to continue with life-saving research. 1. OGT training initiative with CytoCell University … Read More
One dose of a new monoclonal antibody discovered and developed at the National Institutes of Health (NIH) safely prevented malaria for up to nine months in people who were exposed to the malaria parasite. The clinical trial is the first to demonstrate that a monoclonal antibody can prevent malaria… Read More
Terumo Blood and Cell Technologies and PhotonPharma have established a memorandum of understanding (MOU) for collaboration to develop Innocell, a novel tumour specific immunotherapy (a therapeutic vaccine)… Read More
Amgen and the University of Southern California (USC) are working together to provide researchers access to two cryo-transmission electron microscopes (cryo-EMs) – the Thermo Scientific Krios and Glacios. Access to the two instruments in one shared location allows researchers from both institutions to combine resources to bring more speed and… Read More
The European Laboratory Research & Innovation Group (ELRIG) UK has announced programme details for Drug Discovery 2021, which will take place at the Exhibition Centre ACC in Liverpool, UK, from October 19–20. The Society for Laboratory Automation and Screening (SLAS) will host its Innovation AveNEW to showcase emerging innovations and companies. … Read More
A pilot study has begun to assess the antibody response to a third dose of an authorised Covid-19 mRNA vaccine in kidney transplant recipients who did not respond to two doses of the Moderna or Pfizer-BioNTech Covid-19 vaccine. The Phase II trial is sponsored and funded by the National Institute of Allergy and… Read More
Monument Therapeutics, a stratified medicine company, today announced Monument Therapeutics the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director. Monument recently raised £2.625 million in seed funding and applies a novel drug development strategy, leveraging digital assessments of cognition to match patients with new pharmaceutical treatments. The… Read More
An early phase trial of pirfenidone, a drug currently used to treat lung fibrosis, has shown it may also help patients who suffer from a common form of heart failure in a study funded by the National Institute for Health Research, published in Nature Medicine. Trialed in… Read More
Covimro, a British biotech start-up, has developed a food-grade compound which has demonstrated its efficacy against the flu virus in an animal model study carried out by A-IR Clinical Research and Pharmidex Pharmaceutical Services. The in vivo testing analysed Covimro’s antiviral capability against an infection of Influenza A H3N2, a flu variant consistent with… Read More
Sino Biological has announced a successful listing on the Shenzhen Stock Exchange subsidiary ChiNext. A total of 17 million shares were issued for a total of ¥4.98 billion (US$770 million) raised during this initial public offering. Sino Biological says the listing is an important milestone in its strategic plan for growth. It signifies a new starting… Read More
